News|Videos|August 10, 2023

Key Trials in the Treatment of Higher-Risk MDS

Author(s)Rami Komrokji, MD, Andrew Brunner, MD, Hetty Carraway, MD

Dr Zeidan highlights ongoing clinical trials for treatment of higher-risk MDS.

Episodes in this series

EP. 1 Diagnosing Myelodysplastic Syndromes (MDS)

EP. 1 Diagnosing Myelodysplastic Syndromes (MDS)

EP. 2 Risk Stratification of MDS

EP. 2 Risk Stratification of MDS

EP. 3 First-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

EP. 3 First-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

EP. 4 Initiating Treatment for Lower-Risk MDS With Symptomatic Anemia

EP. 4 Initiating Treatment for Lower-Risk MDS With Symptomatic Anemia

EP. 5 Monitoring Treatment With ESAs for Lower-Risk MDS With Symptomatic Anemia

EP. 5 Monitoring Treatment With ESAs for Lower-Risk MDS With Symptomatic Anemia

EP. 6 Second-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

EP. 6 Second-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

EP. 7 Patient Profile: A 75-Year-Old Man With Lower-Risk MDS and Symptomatic Anemia

EP. 8 Treatment Approaches for Lower-Risk MDS With Symptomatic Anemia

EP. 8 Treatment Approaches for Lower-Risk MDS With Symptomatic Anemia

EP. 9 Patient Profile: A 79-Year-Old Man With Lower-Risk MDS and a KRAS Mutation

EP. 10 Treatment Approaches for Lower-Risk MDS With RAS Mutations

EP. 10 Treatment Approaches for Lower-Risk MDS With RAS Mutations

EP. 11 ESA Outcomes by SF3B1 Mutation Status in Lower-Risk MDS

EP. 11 ESA Outcomes by SF3B1 Mutation Status in Lower-Risk MDS

EP. 12 Luspatercept for Lower-Risk MDS: Data From the COMMANDS Trial

EP. 12 Luspatercept for Lower-Risk MDS: Data From the COMMANDS Trial

EP. 13 Imetelstat for Lower-Risk MDS: Data From the IMerge Trial

EP. 13 Imetelstat for Lower-Risk MDS: Data From the IMerge Trial

EP. 14 Oral HMAs in Lower-Risk MDS Treatment

EP. 14 Oral HMAs in Lower-Risk MDS Treatment

EP. 15 IRAK1 and IRAK4 Inhibitors for the Treatment of Lower-Risk MDS

EP. 15 IRAK1 and IRAK4 Inhibitors for the Treatment of Lower-Risk MDS

EP. 16 Key Trials in the Treatment of Higher-Risk MDS

EP. 16 Key Trials in the Treatment of Higher-Risk MDS

EP. 17 Final Thoughts on Recent Data Updates in MDS

EP. 17 Final Thoughts on Recent Data Updates in MDS

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related to this article

The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.

October 24th, 2026

The OncFive: Top Oncology Articles for the Week of 10/18

The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.

FDA

October 22nd, 2026

FDA Grants Orphan Drug Designation to Onvansertib for Chronic Myelomonocytic Leukemia

The oral PLK1 inhibitor onvansertib received FDA orphan drug designation in CMML.

The FDA expands nogapendekin alfa inbakicept in bladder cancer, European regulators back daraxonrasib in pancreatic cancer, and more.

October 17th, 2026

The OncFive: Top Oncology Articles for the Week of 10/11

The FDA expands nogapendekin alfa inbakicept in bladder cancer, European regulators back daraxonrasib in pancreatic cancer, and more.

FDA

October 14th, 2026

FDA Accepts BLA Resubmission for Tabelecleucel in EBV+ Posttransplant Lymphoproliferative Disease

The FDA set a PDUFA target action date of March 31, 2027, for tabelecleucel in relapsed or refractory EBV-positive posttransplant lymphoproliferative disease.

Trending on OncLive

Sacituzumab Govitecan Triplet Elicits Durable Responses in Treatment-Naive Metastatic Urothelial Cancer

Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves ctDNA Clearance in Cisplatin-Eligible MIBC

Ad Hoc Analysis Supports Contributions of Both Enfortumab Vedotin and Pembrolizumab in Cisplatin-Ineligible MIBC

Pembrolizumab Plus Chemo Misses EFS End Point in Cisplatin-Eligible MIBC

Adjuvant Giredestrant Preserves QOL With Sustained Tolerability in ER+, HER2– Early Breast Cancer